glp-1 receptor agonist blue cross blue shield BCBSM pulling back on coverage You might know them as
Description
There are many insurances that have moved toward not having weight loss management as part of their coverage, leaving many patients to cover the costs out of pocket, says Ackah
In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]
doi: 10.2337/dc15-1025 [DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article.
Conclusion: This meta-analysis demonstrates that GLP-1 receptor agonists are a promising therapeutic option for patients with IIH, demonstrating significant efficacy in reducing intracranial pressure-related symptoms such as BMI, headache frequency, papilledema, and visual disturbances
What Is Saxenda
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues
